Controlled release using bilayer osmotic tablet technology: reducing theory to practice

Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice

Volumn , Issue , 2010, Pages 129-153

  Shamblin, Sheri L ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Bilayer osmotic tablets functional swelling layer and manufactured delivery port; Controlled release using bilayer osmotic tablet technology reducing theory to practice; in vitro performance testing tablet release rate measures, in vitro characterization using dissolution testing

Indexed keywords

EID: 79958258569     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470640487.ch9     Document Type: Chapter

References (66)

1. Baker RW. Controlled Release of Biologically Active Agents, John Wiley & Sons, New York, 1987.
2. Cardinal JR. In Amidon GL, Lee PI, Topp EM, editors. Transport Processes in Pharmaceutical Systems, Marcel Dekkar, New York, 2000, pp. 411-444.
3. Kim C. Controlled Release Dosage Form Design, Technomic Publishing Company, Lancaster, PA, 2000.
4. Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. J. Control. Release 1995;35:1-21.
5. Theeuwes F. Elementary osmotic pump. J. Pharm. Sci. 1975; 64:1987-1991.
6. Rose S, Nelson JF. A continuous long-term injector. Aust. J. Exp. Biol. 1955;33:415-420.
7. Am Ende MT, Herbig SM, Korsmeyer RW, Chidlaw MB. In Wise DL, editor. Handbook of Pharmaceutical Controlled Release Technology, Marcel Dekker, New York, 2000, pp. 751-785.
8. Verma RK, Mishra B, Garg S. Osmotically controlled oral drug delivery. Drug Dev. Ind. Pharm. 2000;26(7):695-708.
9. Cardinal JR, Herbig SM, Korsmeyer RW, Lo J, Smith KL, Thombre AG. The use of asymmetric membranes in pharmaceutical delivery devices. EP 357369 A2, 19890829, 1990.
10. Nokhodchi A, Momin MN, Shokri J, Shahsavari M, Rashidi PA. Factors affecting the release of nifedipine from a swellable elementary osmotic pump. Drug Deliv. 2008;15(1): 43-48.
11. Wang X, Nie S-F, Li W, Luan L, Pan W. Studies on bi-layer osmotic pump tablets of water-insoluble allopurinol with large dose: in vitro and in vivo. Drug Dev. Ind. Pharm. 2007;33(9): 1024-1029.
12. Thombre AG. Assessment of the feasibility of oral controlled release in an exploratory development setting. Drug Discov. Today 2005;10(17):1159-1166.
13. Cortese R, Theeuwes F. Osmotic device with hydrogel driving member. EP Patent 52917, 19820602, 1982.
14. Zentner GM, Rork GS, Himmelstein KJ. The controlled porosity osmotic pump. J. Control. Release 1985;1(4):269-282.
15. Jedras Z, Janicki S. In vitro study of gastrointestinal diffusion system using disopyramide phosphate. Pharmazie 1987;42 (12): 842-844.
16. Theeuwes F. Oral dosage forms design: status and goals of oral osmotic systems technology. Pharm. Int. 1984;5:293-296.
17. Thombre AG. Feasibility assessment and rapid development of oral controlled release prototypes. ACS Symp. Ser.; 752 (Controlled Drug Delivery): 2000, 69-77.
18. McConnell EL, Fadda HM, Basit AW. Gut instincts: explorations in intestinal physiology and drug delivery. Int. J. Pharm. 2008;364(2):213-226.
19. Schiller C, Frohlich C-P, Giessmann T, SiegmundW, Monnikes H, Hosten N,WeitschiesW. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment. Pharmacol. Ther. 2005;22(10):971-979.
20. Thombre AG, Appel LE, Chidlaw MB, Daugherity PD, Dumont F, Evans LAF, Sutton SC. Osmotic drug delivery using swellable-core technology. J. Control. Release 2004; 94:75-89.
21. Johnson KC. Dissolution: fundamentals of in vitro release and the biopharmaceutics classification system. Drugs Pharm. Sci. 2007;165(Pharmaceutical Product Development):1-28.
22. Lu ATK, Frisella ME, Johnson KC. Dissolution modeling: factors affecting the dissolution rates of polydisperse powders. Pharm. Res. 1993;10(9):1308-1314.
23. Nie S-F, Li W, Luan L, Pan W, Wang X. Studies on bi-layer osmotic pump tablets of water-insoluble allopurinol with large dose: in vitro and in vivo. Drug Dev. Ind. Pharm. 2007;33 (9):1024-1029.
24. Sastry SV, DeGennaro MD, Reddy IK, Khan MA. Atenolol gastrointestinal therapeutic system. I. Screening of formulation variables. Drug Dev. Ind. Pharm. 1997;23(2):157-165.
25. Poon CY. Remington: The Science and Practice of Pharmacy, Lippincott Williams and Wilkins, New York, 2000.
26. Theeuwes F,Ayer AD. Osmotic devices having composite walls US Patent 4,077,407, 1978.
27. Savastano L, Carr J, Quadros E, Shah S, Khanna SC. Controlled- release osmotic drug delivery devices. EP Patent Application 94-810212 621032, 19940414, 1994.
28. Zaffaroni A, Michaels AS, Theeuwes F. Method for administering drug to the gastrointestinal tract. US Patent 4,096,238, 19780620, 1978.
29. Edgren D, Wong PSL, Theeuwes F. Oral device for osmotic delivery of drugs. US Patent 4503030, 19850305, 1985.
30. Stevens RE, Limsakun T, Evans G, Mason DH, Jr. Controlled, multidose, pharmacokinetic evaluation of two extended-release carbamazepine formulations (Carbatrol and Tegretol-XR). J. Pharm. Sci. 1998;87(12):1531-1534.
31. Guo JH. Effects of plasticizers on water permeation and mechanical properties of cellulose acetate: antiplasticization in slightly plasticized polymer film. Drug Dev. Ind. Pharm. 1993;19(13):1541-1545.
32. Yuan J, Shang PP, Wu SH. Effects of polyethylene glycol on morphology, thermomechanical properties, and water vapor permeability of cellulose acetate-free films. Pharm. Technol. North Am. 2001;25(10):62, 64, 66, 68, 70, 72, 74.
33. Liu L, Xu X. Preparation of bilayer-core osmotic pump tablet by coating the indented core tablet. Int. J. Pharm. 2008; 352 (1-2):225-230.
34. Lin C-W, Cham T-M. Compression behavior and tensile strength of heat-treated polyethylene glycols. Int. J. Pharm. 1995;118:169-179.
35. Yang L, Venkatesh G, Fassihi R. Characterization of compressibility and compactibility of poly(ethylene oxide) polymers for modified release application by compaction simulator. J. Pharm. Sci. 1996;85(10):1085-1090.
36. Yang L,Venkatesh G, Fassihi R. Compaction simulator study of a novel triple-layer tablet matrix for industrial tableting. Int. J. Pharm. 1997;152(1):45-52.
37. Jaminet F, Hess H. Compression and dry granulation. Pharm. Acta Helv. 1966;41(1):39-58.
38. Sanchez-Soto PJ, Gines JM, Arias MJ, Novak C, Ruiz-Conde A. Effect of molecular mass on the melting temperature, enthalpy and entropy of hydroxy-terminated PEO. J. Therm. Anal. Calorim. 2002;67(1):189-197.
39. Bindschaedler C, Gurny R, Doelker E. Osmotically controlled drug delivery systems produced from organic solutions and aqueous dispersions of cellulose acetate. J. Control. Release 1986;4(3):203-212.
40. Kelbert M, Bechard SR. Evaluation of a cellulose acetate (ca) latex as coating material for controlled release products. Drug Dev. Ind. Pharm. 1992;18(5):519-538.
41. Am Ende MT, Berchielli A. A thermodynamic model for organic and aqueous tablet film coating. Pharm. Dev. Technol. 2005;10(1):47-58.
42. Romero-Torres S, Perez-Ramos JD, Morris KR, Grant ER. Raman spectroscopic measurement of tablet-to-tablet coating variability. J. Pharm. Biomed. Anal. 2005;38(2): 270-274.
43. Romero-Torres S, Perez-Ramos JD, Morris KR, Grant ER. Raman spectroscopy for tablet coating thickness quantification and coating characterization in the presence of strong fluorescent interference. J. Pharm. Biomed. Anal. 2006;41(3): 811-819.
44. Geerke JH. Method and apparatus for semipermeable membrane detection in osmotic tablets by near-infrared spectroscopy. US Patent 2007201024, 20070830, 2007.
45. Geerke JH. Method and apparatus for drilling orifices in osmotic tablets incorporating near-infrared spectroscopy. US Patent 2007196487, 20070823, 2007.
46. Malinowski HJ, Morroum PJ. In Mathiowitz E, editor. Encyclopedia of Controlled Drug Delivery, Vol. 1, John Wiley & Sons, Inc., New York, 1999, pp. 381-395.
47. DonbrowM. Stability of the polyoxyethylene chain. Surfactant Sci. Ser. 1987;23(Nonionic Surfactants):1011-1072.
48. Han S, Kim C, Kwon D. Thermal/oxidative degradation and stabilization of polyethylene glycol. Polymer 1997;38: 317-323.
49. Marchal J. Oxidative degradation of polymers and organic compounds via unimolecular decomposition of peroxy radicals. Cent. Rech. Macromol., CNRS 1972.
50. Puz MJ, Johnson BA, Murphy BJ. Use of the antioxidant BHT in asymmetric membrane tablet coatings to stabilize the core to the acid catalyzed peroxide oxidation of a thioether drug. Pharm. Dev. Technol. 2005;10(1):115-125.
51. Elworthy PH, Lipscomb FJ. Solubilization of griseofulvin by nonionic surfactants. J. Pharm. Pharmacol. 1968;20(11): 817-824.
52. Kanagale P, Patel V, Venkatesan N, Jain M, Patel P, Misra A. Pharmaceutical development of solid dispersion based osmotic drug delivery system for nifedipine. Curr. Drug Deliv. 2008;5 (4):306-311.
53. MargaritMV, Rodriguez IC, Cerezo A. Physical characteristics and dissolution kinetics of solid dispersions of ketoprofen and polyethylene glycol 6000. Int. J. Pharm. 1994;108(2): 101-107.
54. Law D, Schmitt EA, Marsh KC, Everitt EA, Wang W, Fort JJ, Krill SL, Qiu Y. Ritonavir-PEG 8000 amorphous solid dispersions: in vitro and in vivo evaluations. J. Pharm. Sci. 2004;93 (3):563-570.
55. Stachurek I, Pielichowski K. Preparation and thermal characterization of poly(ethylene oxide)/griseofulvin solid dispersions for biomedical applications. J. Appl. Polym. Sci. 2009; 111(4):1690-1696.
56. Schachter DM, Xiong J, Tirol GC. Solid state NMR perspective of drug-polymer solid solutions: a model system based on poly(ethylene oxide). Int. J. Pharm. 2004;281(1-2): 89-101.
57. Marsac PJ, Romary DP, Shamblin SL, Baird JA, Taylor LS. Spontaneous crystallinity loss of drugs in the disordered regions of poly(ethylene oxide) in the presence of water. J. Pharm. Sci. 2008;97(8):3182-3194.
58. Schmidt AG, Wartewig S, Picker KM. Polyethylene oxides: protection potential against polymorphic transitions of drugs?. J. Raman Spectrosc. 2004;35(5):360-367.
59. Hancock BC, Parks M. What is the true solubility advantage for amorphous pharmaceuticals?. Pharm. Res. 2000;17(4): 397-404.
60. Hancock BC, Zografi G. Characteristics and significance of the amorphous state in pharmaceutical systems. J. Pharm. Sci. 1997;86:1-12.
61. Kidane A, Ray SK, Bhatt PP, Bryan JW. Osmotic delivery of drugs by solubility enhancement. US Patent Application 2003-655725, 2005053653, 2005.
62. Thombre AG. Delivery device having encapsulated excipients. WO Patent 9412152, 19940609, 1994.
63. Mehramizi A, Asgari ME, Pourfarzib M, Bayati K, Dorkoosh FA, Rafiee-Tehrani M. Influence of b-cyclodextrin complexation on lovastatin release from osmotic pump tablets. DARU 2007;15(2):71-78.
64. Sotthivirat S, Haslam JL, Stella VJ. Evaluation of various properties of alternative salt forms of sulfobutylether-b-cyclodextrin, (SBE)7M-b-CD. Int. J. Pharm. 2007;330(1-2):73-81.
65. Okimoto K, Rajewski RA, Stella VJ. Release of testosterone from an osmotic pump tablet utilizing (SBE)7M-beta-cyclodextrin as both a solubilizing and an osmotic pump agent. J. Control. Release 1999;58(1):29-38.
66. Thombre AG. Delivery device having encapsulated excipients. US Patent 5697922A, 1995.